T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1701
PUT
Herbalife
HLF
$1.28B
| $1.08M | ﹤0.01% |
+50,600
| New | +$864K |
|
1702
Group 1 Automotive
GPI
$3.14B
| $1.08M | ﹤0.01% |
12,500
| – | – |
|
1703
Adeia
ADEA
$3.16B
| $1.07M | ﹤0.01% |
100,775
+32,886
| +48% | +$336K |
|
1704
Cullen/Frost Bankers
CFR
$10.5B
| $1.07M | ﹤0.01% |
15,550
-200
| -1% | -$13.4K |
|
1705
Old Republic International
ORI
$10.3B
| $1.07M | ﹤0.01% |
71,739
+592
| +0.8% | +$8.69K |
|
|
HTD
1706
John Hancock Tax-Advantaged Dividend Income Fund
HTD
$904M
| $1.07M | ﹤0.01% |
50,000
| – | – |
|
|
WNR
1707
DELISTED
Western Refining Inc
WNR
| $1.07M | ﹤0.01% |
21,600
+2,300
| +12% | +$96.1K |
|
|
CVA
1708
DELISTED
Covanta Holding Corporation
CVA
| $1.07M | ﹤0.01% |
47,504
+4,600
| +11% | +$98.5K |
|
|
LXK
1709
DELISTED
Lexmark Intl Inc
LXK
| $1.06M | ﹤0.01% |
25,100
| – | – |
|
1710
Sensient Technologies
SXT
$5.53B
| $1.06M | ﹤0.01% |
15,380
| – | – |
|
1711
Hawaiian Electric Industries
HE
$2.04B
| $1.06M | ﹤0.01% |
32,900
| – | – |
|
1712
Manulife Financial
MFC
$72.9B
| $1.06M | ﹤0.01% |
62,200
-11,382
| -15% | -$196K |
|
|
AMSG
1713
DELISTED
Amsurg Corp
AMSG
| $1.05M | ﹤0.01% |
17,100
| – | – |
|
1714
Tanger
SKT
$4.42B
| $1.05M | ﹤0.01% |
29,780
| – | – |
|
1715
Hyatt Hotels
H
$16.9B
| $1.04M | ﹤0.01% |
17,600
| – | – |
|
1716
Avista
AVA
$3.24B
| $1.03M | ﹤0.01% |
30,290
| – | – |
|
|
GNC
1717
DELISTED
GNC Holdings, Inc.
GNC
| $1.03M | ﹤0.01% |
21,084
+320
| +2% | +$14.8K |
|
|
FNFV
1718
DELISTED
Fidelity Natl Financial, Inc.
FNFV
| $1.03M | ﹤0.01% |
73,188
-1,467,248
| -95% | -$19.8M |
|
|
STR
1719
DELISTED
QUESTAR CORP
STR
| $1.02M | ﹤0.01% |
42,700
-22,075
| -34% | -$539K |
|
1720
TC Energy
TRP
$65.8B
| $1.02M | ﹤0.01% |
23,800
+3,600
| +18% | +$161K |
|
|
DFT
1721
DELISTED
DuPont Fabros Technology Inc.
DFT
| $1.02M | ﹤0.01% |
31,100
+9,500
| +44% | +$321K |
|
1722
Wendy's
WEN
$1.65B
| $1M | ﹤0.01% |
92,215
| – | – |
|
1723
Popular Inc
BPOP
$11.3B
| $1M | ﹤0.01% |
29,185
| – | – |
|
|
BMS
1724
DELISTED
Bemis
BMS
| $1M | ﹤0.01% |
21,600
+17,100
| +380% | +$794K |
|
|
ENH
1725
DELISTED
Endurance Specialty Holdings Ltd
ENH
| $997K | ﹤0.01% |
16,300
| – | – |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.